Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/SER/Return on equity

Serina Therapeutics, Inc. (SER) Return on equity 2017–2024

Serina Therapeutics, Inc. (SER) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.

-1738.1%FY2024 · since FY2017: -90.4% → -1738.1%
17181924
Fiscal yearValueYoY
FY2024-1738.1%—
FY2019-548.0%-447.2 pp
FY2018-100.7%-10.4 pp
FY2017-90.4%—

ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).

Source: SEC XBRL filings · For reference only · Not investment advice

More SER financial trends

SER RevenueSER Net incomeSER Net marginSER Gross profitSER Gross marginSER Operating incomeSER Operating marginSER Operating cash flowSER Free cash flowSER Capital expendituresSER Stock buybacksSER Dividends paidSER Total assetsSER Total liabilitiesSER Shareholders’ equitySER overview →